Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Key Points

• Inhibrx Biosciences CEO Mark Lappe bought more than $3.6 million in shares after the stock fell 17% despite strong Phase 2 clinical data.
• The INBRX-106 combination therapy showed a 48.3% objective response rate versus 26.5% for Keytruda monotherapy in head and neck cancer patients.
• About 28% of the public float is sold short, and heavy insider buying alongside pending FDA action on ozekibart could trigger a short squeeze.

After a decisive clinical outperformance that the broader market inexplicably sold off, Inhibrx Biosciences NASDAQ: INBX CEO deployed more than $3.6 million of personal capital to buy shares. With about 28% of the public float sold short and a major FDA approval date looming, this concentrated insider buying signals a high-probability valuation reset and sets the stage for a potential short squeeze.

Investors tracking clinical-stage biotechnology often look for discrepancies between pipeline progress and share price. When a business posts data nearly doubling the response rate of a standard-of-care oncology drug, the natural expectation is a sharp rally. Instead, Inhibrx Biosciences shares fell 17% over the following weeks.

C-Suite Surgeons: Insiders Buy the Dip

In early September, Inhibrx Biosciences presented primary endpoint results from the Phase 2 portion of its HexAgon study. The data was objectively strong, yet the stock slid on the news. CEO Mark Lappe capitalized on this weakness immediately, acquiring $2.64 million in stock just after the data release. As shares dipped below $100 in late September, Lappe scaled in again, buying an additional 10,000 shares over two days for nearly $1 million.

This level of capital allocation from a chief executive is rarely coincidental. Lappe was not acting alone during this period. Board Director Jon Faiz Kayyem deployed over $1.5 million across three transactions during the same window, while Director Douglas Forsyth also added to his position. Altogether, insiders have purchased approximately $5.5 million in Inhibrx Biosciences stock over the trailing 12 months, with the overwhelming majority concentrated in the last 30 days.

When executives aggressively front-run their own clinical and regulatory pipeline, it indicates an internal consensus that the public market is mispricing the asset. Leadership has access to the granular, day-to-day progress of their clinical trials. Deploying millions into the open market suggests strong confidence that the current share price does not reflect the pipeline's near-term commercial potential.

The Clinical Data Driving Insider Confidence

The fundamental driver validating this C-suite accumulation is the clinical data itself. INBRX-106, a hexavalent OX40 agonist, is currently being evaluated in combination with Keytruda for the first-line treatment of head and neck squamous cell carcinoma. The September Phase 2 readout demonstrated a confirmed objective response rate of 48.3% for the combination arm. By comparison, patients receiving Keytruda monotherapy achieved a 26.5% response rate.

Generating nearly double the response rate of an established standard-of-care therapy, alongside an interim median progression-free survival of 9.6 months, is a notable achievement in oncology development. High objective response rates directly translate into commercial viability and eventual market share. The market's muted reaction likely stems from broader sector fatigue or a routine demand for larger patient sample sizes before assigning a premium valuation. The statistical outperformance remains clear, providing a strong foundation for the upcoming Phase 3 trials.

Beyond the oncology pipeline, Inhibrx Biosciences is nearing a critical inflection point from a clinical-stage cash burner to a commercial-stage enterprise. In June, the U.S. Food and Drug Administration accepted the Biologics License Application for ozekibart, targeting patients with unresectable or metastatic conventional chondrosarcoma. If approved, ozekibart will become the first systemic treatment authorized for this specific rare bone cancer. Securing a first-to-market advantage in an orphan indication unlocks a new, highly defensible revenue stream that carries significant pricing power.

Institutional Immunity and Short Interest

While clinical milestones influence long-term value, Inhibrx Biosciences' short-term trading dynamics are shaped by a small float and substantial short interest. Around 28% of publicly available shares are currently sold short, totaling approximately 3.39 million shares that will need to be repurchased to close these positions. Short sellers are likely betting on continued cash burn and potential equity dilution, a standard playbook for shorting pre-revenue biotech.

Simultaneously, institutional ownership sits above 82%. Tier-one capital is holding the line, absorbing the distribution from retail traders and short sellers during the recent drawdown. This high institutional floor creates friction in the order book. When large funds refuse to lend or sell their shares, the actual tradable float shrinks considerably.

The multi-million dollar insider buying over the last 30 days constricts that float even further. Insiders rarely buy heavily in the open market if a highly dilutive secondary offering is imminent, severely undermining the core short thesis.

If an impending catalyst, such as positive FDA action on ozekibart or an update on the INBRX-106 Phase 3 trial, forces short sellers to cover, they will compete for a rapidly shrinking pool of available shares. This structural dynamic provides the mechanics for a potential short squeeze, where positive fundamental news acts as the ignition for a rapid upward repricing.

The Prescription for Patient Investors

Evaluating any clinical-stage biotech requires an honest assessment of the balance sheet. Inhibrx Biosciences currently has negative shareholders' equity and a trailing EBITDA of approximately -$125 million. This cash-burn reality is the primary anchor weighing on the stock and the central thesis for the short sellers. Developing biologic medicines is capital-intensive, and until a product reaches commercialization, operations rely entirely on cash reserves and access to capital markets.

The bear case points to this negative book value and steady capital erosion. The aggressive insider buying, however, suggests that leadership expects near-term pipeline monetization to decisively outpace existing balance sheet liabilities. Analysts currently model an average 12-month price target of around $197.50, implying an upside potential approaching 94% from current levels.

These projections factor in the probability of regulatory success and the pipeline's commercial viability. The C-suite's willingness to deploy millions of dollars near the $100 level implies they view the current enterprise valuation of $1.5 billion as a floor rather than a ceiling.

Investors navigating this sector must weigh the inherent risks of clinical development against the tangible signals of insider confidence. A $3.6 million vote of confidence from a CEO provides a rare layer of validation to the underlying clinical data, creating a compelling fundamental setup for patient capital.